Lymphovascular invasion (LVI) means that cancer cells have been found inside the small blood vessels or lymphatic channels surrounding a tumor. When a pathologist examines tissue removed during a biopsy or surgery, they sometimes see clusters of tumor cells that have broken through vessel walls and entered the drainage system that connects tissues to lymph nodes and the bloodstream. This is a sign that cancer has begun the process of spreading beyond the original tumor site.
If you’re reading this, you likely saw “lymphovascular invasion present” on a pathology report. Here’s what that finding means in practical terms and why your medical team pays attention to it.
How Cancer Cells Enter Vessels
Tumors are surrounded by a network of tiny lymphatic vessels and capillaries. Lymphatic vessels are thin, endothelial-lined channels that carry fluid and immune cells toward lymph nodes. They lack the muscular walls of larger blood vessels, which makes them easier for cancer cells to penetrate. In LVI, cancer cells break through the basement membrane of these vessels, enter the open channel, and form a small clump called a tumor embolus. From there, cells can travel to nearby lymph nodes or, through blood capillaries, to more distant organs.
This process is actually difficult to catch on a pathology slide. The moment when cancer cells are actively pushing into a vessel is brief, so what pathologists typically see is the result: a cluster of tumor cells sitting inside a vessel space.
How Pathologists Identify It
On a standard tissue slide stained with routine dyes (hematoxylin and eosin), pathologists look for tumor cell clusters clearly sitting within a vessel channel, surrounded by an endothelial lining. One challenge is distinguishing true LVI from something called retraction artifact, which is a common lab processing effect where tissue shrinks away from tumor clusters, creating empty spaces that can mimic vessels. Experienced pathologists use specific visual criteria to tell the difference.
When the standard slide is ambiguous, pathologists can use special stains. A marker called D2-40 highlights lymphatic vessels specifically, while CD31 marks blood vessel walls. In one study of prostate cancer specimens, these immunostains confirmed every case of LVI that had been identified on routine slides and further revealed tumor cells in 47 lymphatic vessels and 16 blood vessels across 50 tissue blocks. These tools help reduce both false positives and missed cases.
Lymphatic Versus Blood Vessel Invasion
LVI is sometimes reported as a single finding, but the 8th edition of the AJCC Cancer Staging Manual recommends that lymphatic invasion and blood vessel (vascular) invasion be reported separately, because they carry slightly different prognostic weight.
A large meta-analysis of esophageal cancer studies found that both types predicted worse overall survival. Lymphatic invasion, however, was the stronger predictor when it came to recurrence-free survival, meaning the time a patient stays cancer-free after treatment. In that analysis, lymphatic invasion was associated with a 71% higher risk of recurrence, while blood vessel invasion showed a 28% increase that did not reach statistical significance. In other words, cancer cells in lymphatic channels appear to be a more reliable warning sign for the cancer coming back.
Why LVI Matters for Prognosis
The presence of LVI consistently signals a higher risk of both local recurrence and distant spread across multiple cancer types, including breast, colorectal, gastric, and esophageal cancers. It tells your oncologist that the tumor had already begun the biological process of metastasis at the time it was removed.
In early-stage breast cancer treated with mastectomy, the numbers are striking. Patients whose tumors showed LVI had locoregional recurrence rates of 9.5% at eight years, compared to just 1% in patients without LVI. Regional recurrence followed a nearly identical pattern: 9.4% versus 1.1%. Separately, a study of lymph node-positive breast cancer found that five-year metastasis-free survival was 80.1% in patients with LVI, compared to 91.5% in patients without it. That roughly 11-percentage-point gap reflects the added risk of cancer eventually appearing in distant organs like the lungs, liver, or bones.
How LVI Affects Staging and Treatment Decisions
LVI is not part of the standard T, N, or M categories in most cancer staging systems, but it increasingly influences how doctors interpret those stages. In gastric cancer, for example, researchers have shown that patients with no lymph node involvement (N0) but positive LVI behave more like patients who do have lymph node spread (N1). One study reclassified 104 gastric cancer patients this way, upgrading their stage based on LVI status alone, and found that the revised staging more accurately predicted outcomes.
For treatment planning, LVI is one of several factors that can tip the balance toward more aggressive therapy. In breast cancer, its presence may support recommending radiation after mastectomy, additional chemotherapy, or closer surveillance. It does not automatically mean you need a specific treatment, but it gives your oncologist a clearer picture of how the tumor was behaving biologically. Combined with tumor size, grade, hormone receptor status, and lymph node findings, LVI helps build a more complete risk profile that guides the conversation about next steps.
What “LVI Not Identified” Means
If your pathology report says lymphovascular invasion is not identified or absent, that’s a favorable finding. It means that on the tissue sections examined, there was no evidence of tumor cells inside vessels. This is associated with lower recurrence rates and better long-term outcomes across virtually all solid tumor types. Keep in mind that pathologists can only evaluate the tissue they receive, so “not identified” reflects what was seen in the sampled sections rather than an absolute guarantee about the entire tumor. Still, it is a genuinely reassuring result that factors positively into your overall prognosis.